International Speaker: Dr Michael Rosenzweig, Ph.D., Executive Director, Biology-Discovery, IMR Early Discovery, Merck Research Laboratories
What’s next for cancer immunotherapies? Targeting T cell checkpoint proteins have delivered amazing results for cancer treatment, but not all patients respond. Pushing forward into new frontiers, harnessing the innate immune system could be the next-big thing to drive immuno-oncology success to the next level.
Michael Rosenzweig is the Executive Director of Oncology Discovery in Boston where he leads the team developing new therapeutics targeting cancer and autoimmunity. A major focus of the team is to build a pipeline to follow on the success of Keytruda®.
Michael joined Merck in 2014 with more than 15 years of experience in biologics drug development, particularly in the fields of oncology, immunology and infectious diseases. He previously served as the VP of Research at Immunext and has held various positions in Biotechnology companies including Tolerx and Cordlife.
Michael received his DVM from the University of Pretoria in South Africa and a PhD in Immunology from the University of Pennsylvania. He then joined Harvard University where he was on the faculty at New England Primate Research Center.
Presentation : Emerging Innate Immune Targets for Enhancing Adaptive Anti-Tumor Responses
Novel cancer immunotherapies targeting T cell checkpoint proteins have emerged as powerful tools to induce profound, durable regression and remission of many types of cancer. Despite these advances, multiple studies have demonstrated that not all patients respond to these therapies, and the ability to predict which patients may respond is limited. Harnessing the innate immune system to augment the adaptive anti-tumor response represents an attractive target for therapy, which has the potential to enhance both the percentage and rate of response to checkpoint blockade.
Date: Monday 10th October, 2016
Time: 3:45 registration for 4:00pm – 5:15pm followed by a networking session
Venue: Allens, Level 37, 101 Collins Street, Melbourne
Members – $65
Non-Members – $130
(Prices include GST)
To check if your organisation is a member click here
63 people are attending Fully Booked – 10th October – BioBriefing – Novel Cancer Immunotherapies